id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-319013-oytqcifa	Focosi, Daniele	Convalescent Plasma Therapy for COVID-19: State of the Art	2020-08-12		.txt	text/plain	7474	335	41	In the first retrospective, randomized controlled trial published to date, 39 patients in New York with severe COVID-19 were transfused with 2 units of ABO-type matched CP with anti-Spike antibody titers of Ն1:320 (measured by a two-step Spike proteindirected ELISA). CP (9 to 13 ml/kg from donors with S-RBD IgG titer of Ն1:640) was associated with a negative SARS-CoV-2 PCR test at 72 h in 87.2% of the CP group versus 37.5% of the BSC group, but clinical improvement at 28 days was statistically different only in patients with severe, but not in life-threatening, disease (104) . Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol Anti-SARS-CoV-2 virus antibody levels in convalescent plasma of six donors who have recovered from COVID-19	./cache/cord-319013-oytqcifa.txt	./txt/cord-319013-oytqcifa.txt